Table 2. The detailed clinical data of the three subtypes of lung adenocarcinoma.
| Covariates | Cluster | Total | C1 | C2 | C3 | P value |
|---|---|---|---|---|---|---|
| Age (years) | ≤65 | 224 (47.97%) | 107 (51.94%) | 60 (52.63%) | 57 (38.78%) | 0.02 |
| >65 | 233 (49.89%) | 98 (47.57%) | 49 (42.98%) | 86 (58.5%) | ||
| Unknown | 10 (2.14%) | 1 (0.49%) | 5 (4.39%) | 4 (2.72%) | ||
| Gender | Female | 254 (54.39%) | 107 (51.94%) | 54 (47.37%) | 93 (63.27%) | 0.02 |
| Male | 213 (45.61%) | 99 (48.06%) | 60 (52.63%) | 54 (36.73%) | ||
| Stage | Stage I | 253 (54.18%) | 101 (49.03%) | 50 (43.86%) | 102 (69.39%) | <0.01 |
| Stage II | 107 (22.91%) | 54 (26.21%) | 28 (24.56%) | 25 (17.01%) | ||
| Stage III | 74 (15.85%) | 39 (18.93%) | 24 (21.05%) | 11 (7.48%) | ||
| Stage IV | 25 (5.35%) | 10 (4.85%) | 10 (8.77%) | 5 (3.4%) | ||
| Unknown | 8 (1.71%) | 2 (0.97%) | 2 (1.75%) | 4 (2.72%) | ||
| T | T1 | 159 (34.05%) | 58 (28.16%) | 25 (21.93%) | 76 (51.7%) | <0.01 |
| T2 | 248 (53.1%) | 122 (59.22%) | 71 (62.28%) | 55 (37.41%) | ||
| T3 | 39 (8.35%) | 17 (8.25%) | 13 (11.4%) | 9 (6.12%) | ||
| T4 | 18 (3.85%) | 9 (4.37%) | 4 (3.51%) | 5 (3.4%) | ||
| Unknown | 3 (0.64%) | 0 (0%) | 1 (0.88%) | 2 (1.36%) | ||
| M | M0 | 314 (67.24%) | 138 (66.99%) | 79 (69.3%) | 97 (65.99%) | 0.15 |
| M1 | 24 (5.14%) | 10 (4.85%) | 10 (8.77%) | 4 (2.72%) | ||
| Unknown | 129 (27.62%) | 58 (28.16%) | 25 (21.93%) | 46 (31.29%) | ||
| N | N0 | 302 (64.67%) | 121 (58.74%) | 68 (59.65%) | 113 (76.87%) | <0.01 |
| N1 | 86 (18.42%) | 43 (20.87%) | 24 (21.05%) | 19 (12.93%) | ||
| N2 | 65 (13.92%) | 38 (18.45%) | 21 (18.42%) | 6 (4.08%) | ||
| N3 | 2 (0.43%) | 2 (0.97%) | 0 (0%) | 0 (0%) | ||
| Unknown | 12 (2.57%) | 2 (0.97%) | 1 (0.88%) | 9 (6.12%) |
C1, Cluster 1; C2, Cluster 2; C3, Cluster 3.